S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.75 (-1.80%)
MSFT   285.78 (-2.85%)
FB   342.87 (-3.03%)
GOOGL   2,739.25 (-2.91%)
TSLA   782.63 (-1.10%)
AMZN   3,326.96 (-2.31%)
NVDA   209.13 (-3.45%)
BABA   152.97 (+1.86%)
NIO   35.31 (-3.97%)
CGC   14.30 (-2.79%)
GE   106.61 (+1.20%)
MU   74.06 (-1.49%)
AMD   102.63 (-5.11%)
T   27.33 (-0.26%)
F   14.42 (+1.84%)
ACB   6.83 (+6.89%)
DIS   175.46 (-1.57%)
PFE   43.24 (-0.76%)
BA   220.26 (-1.74%)
AMC   37.96 (-3.41%)
NASDAQ:CDNA

CareDx Stock Forecast, Price & News

$59.46
-2.49 (-4.02 %)
(As of 09/28/2021 03:27 PM ET)
Add
Compare
Today's Range
$58.44
$62.82
50-Day Range
$61.95
$87.51
52-Week Range
$32.63
$99.83
Volume49,441 shs
Average Volume637,737 shs
Market Capitalization$3.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.61
30 days | 90 days | 365 days | Advanced Chart
Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.


CareDx logo

About CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in South San Francisco, CA.

Headlines

CareDx Presents Latest Data on AlloSeq Portfolio at ASHI 2021
September 27, 2021 |  finance.yahoo.com
CareDx (NASDAQ:CDNA) Stock Price Up 3.1%
September 14, 2021 |  americanbankingnews.com
Monday's ETF Movers: URA, PTH - Nasdaq
September 13, 2021 |  nasdaq.com
Oversold Conditions For CareDx (CDNA) - Nasdaq
September 13, 2021 |  nasdaq.com
CareDx (NASDAQ:CDNA) Shares Down 7.9%
September 13, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDNA
Employees
466
Year Founded
N/A

Sales & Book Value

Annual Sales
$192.19 million
Book Value
$5.64 per share

Profitability

Net Income
$-18,710,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$3.13 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.92 out of 5 stars

Medical Sector

660th out of 1,353 stocks

Medical Laboratories Industry

16th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












CareDx (NASDAQ:CDNA) Frequently Asked Questions

Is CareDx a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CareDx stock.
View analyst ratings for CareDx
or view top-rated stocks.

What stocks does MarketBeat like better than CareDx?

Wall Street analysts have given CareDx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CareDx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CareDx's next earnings date?

CareDx is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for CareDx
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) released its quarterly earnings data on Thursday, July, 29th. The company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.05. The business had revenue of $74.19 million for the quarter, compared to the consensus estimate of $68.02 million. CareDx had a negative net margin of 3.53% and a negative trailing twelve-month return on equity of 2.39%.
View CareDx's earnings history
.

How has CareDx's stock price been impacted by Coronavirus?

CareDx's stock was trading at $18.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDNA stock has increased by 213.9% and is now trading at $59.46.
View which stocks have been most impacted by COVID-19
.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $280 million-$290 million, compared to the consensus revenue estimate of $278.39 million.

What price target have analysts set for CDNA?

6 equities research analysts have issued 12 month price targets for CareDx's shares. Their forecasts range from $55.00 to $115.00. On average, they expect CareDx's stock price to reach $96.17 in the next year. This suggests a possible upside of 61.7% from the stock's current price.
View analysts' price targets for CareDx
or view top-rated stocks among Wall Street analysts.

Who are CareDx's key executives?

CareDx's management team includes the following people:
  • Reginald Seeto, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Paul Ciccolella, Senior Vice President-Global Operations
  • Ankur Dhingra, Chief Financial & Accounting Officer
  • Amitabh Shukla, Senior Vice President-Technology
  • Sham Dholakia, Senior VP-Medical Affairs & Clinical Operations

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Square (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.95%), ARK Investment Management LLC (8.67%), BlackRock Inc. (8.03%), Invesco Ltd. (5.62%), Matrix Capital Management Company LP (3.31%) and Clearbridge Investments LLC (3.14%). Company insiders that own CareDx stock include George Bickerstaff, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends for CareDx
.

Which major investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, State Street Corp, FMR LLC, Balyasny Asset Management LLC, Ziegler Capital Management LLC, Credit Suisse AG, Nuveen Asset Management LLC, and Next Century Growth Investors LLC. Company insiders that have sold CareDx company stock in the last year include George Bickerstaff, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas, and William A Hagstrom.
View insider buying and selling activity for CareDx
or view top insider-selling stocks.

Which major investors are buying CareDx stock?

CDNA stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Millennium Management LLC, Morgan Stanley, Morgan Stanley, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Conestoga Capital Advisors LLC, and ArrowMark Colorado Holdings LLC.
View insider buying and selling activity for CareDx
or or view top insider-buying stocks.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $59.46.

How much money does CareDx make?

CareDx has a market capitalization of $3.13 billion and generates $192.19 million in revenue each year. The company earns $-18,710,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does CareDx have?

CareDx employs 466 workers across the globe.

What is CareDx's official website?

The official website for CareDx is www.caredxinc.com.

Where are CareDx's headquarters?

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (415) 287-2300 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.